These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 24408866)

  • 1. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
    Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
    Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
    Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.
    Loilome W; Yooyuen S; Namwat N; Sithithaworn P; Puapairoj A; Kano J; Noguchi M; Miwa M; Yongvanit P
    Tumour Biol; 2012 Dec; 33(6):2289-98. PubMed ID: 22922884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular aspects of cholangiocarcinoma.
    Kiguchi K
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis.
    Chusorn P; Namwat N; Loilome W; Techasen A; Pairojkul C; Khuntikeo N; Dechakhamphu A; Talabnin C; Chan-On W; Ong CK; Teh BT; Yongvanit P
    Tumour Biol; 2013 Jun; 34(3):1579-88. PubMed ID: 23417858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovering proteins for chemoprevention and chemotherapy by curcumin in liver fluke infection-induced bile duct cancer.
    Khoontawad J; Intuyod K; Rucksaken R; Hongsrichan N; Pairojkul C; Pinlaor P; Boonmars T; Wongkham C; Jones A; Plieskatt J; Potriquet J; Bethony JM; Mulvenna J; Pinlaor S
    PLoS One; 2018; 13(11):e0207405. PubMed ID: 30440021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasonography as a tool for monitoring the development and progression of cholangiocarcinoma in Opisthorchis viverrini/ dimethylnitrosamine-induced hamsters.
    Plengsuriyakarn T; Eursitthichai V; Labbunruang N; Na-Bangchang K; Tesana S; Aumarm W; Pongpradit A; Viyanant V
    Asian Pac J Cancer Prev; 2012; 13(1):87-90. PubMed ID: 22502719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    Ilyas SI; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel carbohydrate antigen expression during development of Opisthorchis viverrini- associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis.
    Sawanyawisuth K; Silsirivanit A; Kunlabut K; Tantapotinan N; Vaeteewoottacharn K; Wongkham S
    Parasitol Int; 2012 Mar; 61(1):151-4. PubMed ID: 21784171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target.
    Sawanyawisuth K; Wongkham C; Pairojkul C; Saeseow OT; Riggins GJ; Araki N; Wongkham S
    Acta Oncol; 2007; 46(3):378-85. PubMed ID: 17450475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression.
    Dokduang H; Techasen A; Namwat N; Khuntikeo N; Pairojkul C; Murakami Y; Loilome W; Yongvanit P
    J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):767-76. PubMed ID: 25044480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
    Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
    Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
    Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of oxysterol binding protein isoforms in opisthorchiasis-associated cholangiocarcinoma: a potential molecular marker for tumor metastasis.
    Loilome W; Wechagama P; Namwat N; Jusakul A; Sripa B; Miwa M; Kuver R; Yongvanit P
    Parasitol Int; 2012 Mar; 61(1):136-9. PubMed ID: 21763455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N; Vogel A
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
    Loilome W; Namwat N; Jusakul A; Techasen A; Klanrit P; Phetcharaburanin J; Wangwiwatsin A
    Recent Results Cancer Res; 2023; 219():53-90. PubMed ID: 37660331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein Kinases as Targets for Opisthorchis viverrini- Associated Cholangiocarcinoma Therapy.
    Loilome W; Dokduang H
    Curr Pharm Des; 2017 Nov; 23(29):4281-4289. PubMed ID: 28699535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.